Andrej Schmidt1, Michael Piorkowski2, Henrik Görner3, Sabine Steiner3, Yvonne Bausback3, Susanne Scheinert3, Ursula Banning-Eichenseer3, Holger Staab4, Daniela Branzan4, Ramon L Varcoe5, Dierk Scheinert3. 1. Department of Interventional Angiology, University Hospital Leipzig and Center of Vascular Medicine, Angiology and Vascular Surgery Park Hospital Leipzig, Germany. Electronic address: dr.andrej.schmidt@gmail.com. 2. Cardioangiological Center Bethanien, Frankfurt, Germany. 3. Department of Interventional Angiology, University Hospital Leipzig and Center of Vascular Medicine, Angiology and Vascular Surgery Park Hospital Leipzig, Germany. 4. Department of Vascular Surgery, University Hospital Leipzig, Germany. 5. Department of Surgery, Prince of Wales Hospital and University of New South Wales, Sydney, Australia.
Abstract
OBJECTIVES: The authors sought to investigate the efficacy of a drug-coated balloon (DCB) for treatment of complex femoropopliteal lesions. BACKGROUND: Superiority of DCBs compared with uncoated balloon angioplasty for femoropopliteal interventions has been demonstrated in randomized trials for short lesions. Their performance in complex lesions with higher restenosis rates is unclear. METHODS: Patency, target lesion revascularization (TLR) rate, clinical improvement, and safety endpoints of femoropopliteal lesions in 288 limbs (n = 260) treated with the In.Pact Pacific or Admiral DCB (Medtronic, Minneapolis, Minnesota) were retrospectively analyzed for up to 2 years of follow-up. Predictors of restenosis were identified by logistic regression. RESULTS: Lesions were de novo in 51.7%, restenosis in 11.1%, and in-stent restenosis in 37.2%. Mean lesion length was 24.0 ± 10.2 cm, and 65.3% were occluded. Stent implantation was performed in 23.3%. Kaplan Meier estimates of primary patency were 79.2% and 53.7% for all lesions at 1 and 2 years, respectively, whereas freedom from TLR was 85.4% and 68.6%. Primary patency for in-stent restenosis treatment was 76.6% and 48.6%, and freedom from TLR was 83.0% and 58.7% at 1 and 2 years, respectively. Rutherford category improved from a median 3.3 to 1.2 at 1 year, and to 1.1 at 2 years. Major amputation rate was 2.1% at 2 years. No adverse events were thought to be attributable to the coating of the balloon. CONCLUSIONS: These results suggest that DCB are safe and effective in delaying rather than preventing restenosis in long, complex lesions and restenosis of the femoropopliteal tract. Further studies are recommended to confirm these results.
OBJECTIVES: The authors sought to investigate the efficacy of a drug-coated balloon (DCB) for treatment of complex femoropopliteal lesions. BACKGROUND: Superiority of DCBs compared with uncoated balloon angioplasty for femoropopliteal interventions has been demonstrated in randomized trials for short lesions. Their performance in complex lesions with higher restenosis rates is unclear. METHODS: Patency, target lesion revascularization (TLR) rate, clinical improvement, and safety endpoints of femoropopliteal lesions in 288 limbs (n = 260) treated with the In.Pact Pacific or Admiral DCB (Medtronic, Minneapolis, Minnesota) were retrospectively analyzed for up to 2 years of follow-up. Predictors of restenosis were identified by logistic regression. RESULTS: Lesions were de novo in 51.7%, restenosis in 11.1%, and in-stent restenosis in 37.2%. Mean lesion length was 24.0 ± 10.2 cm, and 65.3% were occluded. Stent implantation was performed in 23.3%. Kaplan Meier estimates of primary patency were 79.2% and 53.7% for all lesions at 1 and 2 years, respectively, whereas freedom from TLR was 85.4% and 68.6%. Primary patency for in-stent restenosis treatment was 76.6% and 48.6%, and freedom from TLR was 83.0% and 58.7% at 1 and 2 years, respectively. Rutherford category improved from a median 3.3 to 1.2 at 1 year, and to 1.1 at 2 years. Major amputation rate was 2.1% at 2 years. No adverse events were thought to be attributable to the coating of the balloon. CONCLUSIONS: These results suggest that DCB are safe and effective in delaying rather than preventing restenosis in long, complex lesions and restenosis of the femoropopliteal tract. Further studies are recommended to confirm these results.
Authors: Abhisekh Mohapatra; Zein Saadeddin; Daniel J Bertges; Michael C Madigan; Georges E Al-Khoury; Michel S Makaroun; Mohammad H Eslami Journal: J Vasc Surg Date: 2019-08-10 Impact factor: 4.268
Authors: Ali F AbuRahma; Zachary T AbuRahma; Grant Scott; Elliot Adams; Matthew Beasley; Meghan Davis; L Scott Dean; Elaine Davis Journal: J Vasc Surg Date: 2019-08-08 Impact factor: 4.268
Authors: Herman Schroë; Andrew H Holden; Yann Goueffic; Shirley J Jansen; Patrick Peeters; Koen Keirse; Wulf Ito; Frank Vermassen; Antonio Micari; Erwin Blessing; Michael R Jaff; Thomas Zeller Journal: Catheter Cardiovasc Interv Date: 2017-10-31 Impact factor: 2.692
Authors: Mariya Kronlage; Maximilian Wassmann; Britta Vogel; Oliver J Müller; Erwin Blessing; Hugo Katus; Christian Erbel Journal: Drug Des Devel Ther Date: 2017-10-06 Impact factor: 4.162
Authors: Julio Cesar Peclat de Oliveira; Ana Paula Rolim Maia Peclat; Fernando Tebet Ramos Barreto; João Marcos Fonseca; Diogo Di Batista de Abreu E Souza; Stenio Karlos Alvim Fiorelli; Rossano Kepler Alvim Fiorelli; Marcos Arêas Marques Journal: J Vasc Bras Date: 2017 Jan-Mar